The US Food and Drug Administration (FDA) has approved a once-daily treatment with netarsudil and latanoprost ophthalmic solution (Rocklatan, Aerie Pharmaceuticals) to decrease elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, the company has announced.

Rocklatan is the first and only once-daily, fixed-dose combination of a prostaglandin analog (latanoprost) and the first-in-class rho-associated protein kinase (ROCK) inhibitor (netarsudil), according to the company.

Netarsudil is the active ingredient in Rhopressa (Aerie Pharmaceuticals), which was approved by the FDA in February 2018 as a once-daily treatment for open-angle glaucoma or ocular hypertension. Netarsudil targets the trabecular outflow pathway, countering the stiffening and contraction of the meshwork that elevates ocular pressure.

Click here to read the full article.

Author